ReviewiScience2025
Metastatic hepatic carcinoma: Mechanisms, emerging therapeutics, and future perspectives.
Review in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- From Gut Microbiota to Hepatic Pre-Metastatic Niches: Mechanism and Translational Prospects of the Gut-Liver Axis in Regulating Colorectal Cancer Liver Metastasis.Microorganisms · 2026Review
- An Exosome-Liposome Hybrid Platform for Celastrol Delivery Enhances Anti-Tumor Efficacy in Hepatocellular Carcinoma.Current topics in medicinal chemistry · 2026Article
- Retrospective Analysis of the Clinical Efficacy, Safety, and Influencing Factors of Drug-Eluting Bead Transarterial Chemoembolization for Unresectable Hepatic Malignancies.Clinical Medicine Insights. Oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metastatic hepatic carcinoma (MHC) remains a lethal disease, with a 5-year survival rate of around 14%. Although early-stage MHC can be managed through surgery, with or without adjuvant chemotherapy, it remains ultimately incurable due to the presence of disseminated cancer cells, including metastasis-competent cells that are resistant to therapy. Recent research has focused on uncovering the molecular mechanisms driving MHC and addressing the limitations of current treatment strategies. This review highlights newly discovered factors involved in the dissemination of liver cancer cells and their colonization of distant organs, such as genetic mutations, metastasis-initiating cells, epithelial-mesenchymal transition, and the tumor microenvironment. Furthermore, recent advances in precision medicine, genomic profiling, and immunotherapy have made notable strides in improving the treatment landscape for MHC. Thus, we review the state of emerging therapies and outlines future directions for more precise and effective treatment strategies in MHC, such as precision medicine, immunotherapy, bacterial therapy, nanotechnology, and artificial intelligence, offering promising directions for future clinical management of MHC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.